INSMED INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
INSMED INC (INSM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $36.58 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-02-19
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $15.70, a 8.28% increase year-over-year.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $14.50, a 12.49% decline year-over-year.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2016-03-31 was $16.57, a 14.35% increase year-over-year.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2015-03-31 was $14.49.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $36.58, a 55.79% increase from fiscal 2024.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $23.48, a 2.21% decline from fiscal 2023.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $24.01, a 6.58% decline from fiscal 2022.
- INSMED INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $25.70, a 5.54% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $36.58 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $23.48 10-K · filed 2025-02-20 | |||
| 2023-12-31 | $24.01 10-K · filed 2025-02-20 | |||
| 2022-12-31 | $25.70 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $24.35 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $23.98 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $19.02 10-K · filed 2022-02-17 | |||
| 2018-12-31 | $19.79 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $19.15 10-Q · filed 2018-10-30 | |||
| 2018-06-30 | $17.30 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $15.70 10-Q · filed 2018-05-02 | |||
| 2017-12-31 | $15.50 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $15.59 10-Q · filed 2017-11-02 | |||
| 2017-06-30 | $15.53 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $14.50 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $17.08 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $16.29 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $16.48 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $16.57 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | $15.43 10-K · filed 2018-02-23 | |||
| 2015-09-30 | $14.93 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $14.10 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $14.49 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $11.42 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $9.78 10-Q · filed 2014-11-06 | |||
| 2014-06-30 | $11.27 10-Q · filed 2014-08-06 | |||
| 2013-12-31 | $10.49 10-K · filed 2016-02-25 | |||
| 2013-09-30 | $10.03 10-Q · filed 2013-11-05 | |||
| 2013-06-30 | $12.80 10-Q · filed 2013-08-06 | |||
| 2013-03-31 | $10.10 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $9.54 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $26.57 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |